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Abstract: 
Carriers are often an essential element of drug delivery, bestowing attributes to their cargo such as 
biocompatibility, enhanced delivery, extended half-life and efficacy as well as mediating specific 
targeting at a tissue, cell or intracellular level.  Liposomes and lipid-based carriers have been 
investigated for decades for this purpose, many achieving clinical approval including products such as 
Doxil™ and Myocet™.  However, reports also indicate issues with the use of cationic lipids, toxicity in 
particular.  It is important to consider that carrier or vector systems engineered to efficiently deliver a 
drug may not be inert.  Large-scale compound screens are routinely carried out in the field of drug 
discovery; however less work has been done on harnessing high throughput methods for carrier 
material screening. Screening the interaction of drug carriers and materials with cells is particularly 
critical for the development of emerging therapies, including biomedicines, in order to facilitate the 
development of safe and efficient drug products.  Herein, a range of liposomes of neutral, anionic and 
cationic charge and others that are surface-modified with mannose residues were screened for cell 
interaction, toxicity and immune reactivity in THP-1-derived macrophages using a high throughput 
format.   
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Introduction 
Over the last decade high throughput screening of compound libraries has become a significant 
phase in the drug discovery and development process. With a growing range of materials now being 
developed for use as drug carriers, a need for high throughput screening methods for drug delivery 
systems is equally critical. This is of particular importance for cellular delivery where an understanding 
of cellular interaction, uptake and cytotoxicity is critical when comparing and optimising delivery 
systems (Forbes et al., 2014).   
 
Liposomes have been evaluated for decades as drug carriers due in part to their versatility.  They 
boast a great number of benefits over other drug carrier systems such as the capability of entrapping 
a wide range of drugs, biocompatibility and low toxicity (Malmsten, 2002) and are the most 
extensively explored delivery system for phagocyte-targeted therapies. Drug delivery to phagocytic 
cells such as monocytes, dendritic cells and macrophages represents an important therapeutic 
approach to treat inflammatory diseases and pathogenic infections through manipulation of the 
immune response.     
 
Liposome drug delivery systems can be formulated to exploit the physiological role of cells to provide 
specific targeting and enhance drug efficacy. Currently, there are several FDA approved liposome-
based products available for the delivery of drugs such as amphotericin B (AmBisome®, ABELCET® 
and Amphocil) and doxorubicin (Doxil®) (Puri et al., 2009).  Although there are a number of 
amphotericin B liposome therapeutics available, the configuration of each differ considerably in terms 
of lipid composition, shape, size, stability, pharmacokinetics and toxicity. For example AmBiosome® 
liposomes are spherical in structure and <100 nm in diameter whereas ABELCET® liposomes are 
ribbon-like structures, 1.6 µm-11µm in diameter and associated with mild nephrotoxicity  (Adler-Moore 
and Proffitt, 2008).   
 
Cationic liposomes are associated with efficient cellular delivery of drug cargoes and are routinely 
applied for in vitro gene delivery (Zuhorn et al., 2007).  Electrostatic interactions between positively 
charged liposomes and negatively charged cell membranes and cell surface proteoglycans (Wiethoff 
et al., 2001) facilitate cell uptake.  Unfortunately, cationic liposomes can cause cytotoxicity, thereby 
limiting their safety for clinical use (Lv et al., 2006).  Cationic liposomes containing stearylamine (SA) 
have previously been shown to induce apoptosis through mitochondrial pathways in RAW264.7 
macrophages by generating reactive oxygen species (ROS), releasing cytochrome c, caspase-3 and -
8 and activating protein kinase C delta (PKCδ) possibly through cell surface proteoglycan interaction 
(Iwaoka et al., 2006, Aramaki et al., 2001, Arisaka et al., 2010, Takano et al., 2003).  Consequently, 
interest has turned to neutral and anionic liposomes for drug delivery applications.   
 
Several studies have shown enhanced uptake of anionic liposomes by macrophages.  In eukaryotic 
cells, apoptosis results in phosphatidylserine (PS), an anionic lipid, being exposed on the outer cell 
surface and the stimulation of monocytic phagocytosis, most likely via scavenger receptors (SRs) 
(Moghimi and Hunter, 2001) and cell-surface glycoproteins (Kobayashi et al., 2007).  Therefore PS 
composed liposomes could target these receptors.  Another strategy for liposomal macrophage 
targeting involves coating liposomes with ligands such as antibodies, peptides and lectins (Kelly et al., 
2011).  For instance, mannosylated liposomes target the mannose receptor (MR) of macrophages 
and facilitate improved cellular uptake both in vitro and in vivo over non-ligand coated liposomes 
(Chono et al., 2009, Chono et al., 2007, Engel et al., 2003, Espuelas et al., 2008, Wijagkanalan et al., 
2008b, Kawakami et al., 2000a, Kawakami et al., 2000b). The MR is involved in a range of processes 
including the recognition and internalisation of both foreign and self-materials, antigen presentation 
and intracellular signalling (Gazi and Martinez-Pomares, 2009).  Moreover, mannose receptor 
activation has been linked to the initiation of an anti-inflammatory immunosuppressive programme in 
cells (Chieppa et al., 2003) and impaired NFκB activation (Xu et al., 2010), thus arguing for the utility 
of targeting strategies aimed at binding the MR, such as mannosylated liposomes.   
 
Hence, it is clear from the outset that targeted drug carriers can elicit responses related to not only 
toxicity and immune reactivity in macrophages but also more subtle cell signalling pathway effects. 
When tasked with developing a macrophage-targeted delivery system it is therefore critical that 
comprehensive and rapid tools are available for screening of potential carriers to determine lead 
formulations for progress to pre-clinical in vivo testing. In this study, a range of different liposomes 
were prepared representing cationic, anionic, uncharged (neutral) and coated (mannosylated) classes 
and high throughput in vitro screening techniques were explored to assess targeted uptake, 
cytotoxicity and ability to activate macrophages in a human macrophage cell model. Liposomes were 
seen to be efficacious in a concentration-dependent and mannosylated cholesterol linker length-
dependent manner. 
Methods 
 
Liposome Preparation 
Cholesten-5-yloxy-N-(4-((1-imino-2-α-thioglycosylethyl)amino)butyl)formamide (Mann-C4-Chol) and 
its C2 and C6 derivatives were synthesized using a method described previously by Kawakami et al. 
(Kawakami et al., 2000a).  Mannosylated cholesterol derivatives differ by their carbon linker lengths 
(C2, C4 and C6).  Phospholipids 1,2-Dioleoyl-3-trimethylammonium-propane (DOTAP), 1,2-dioleoyl-
sn-glycero-3-phosphocholine (DOPC), 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS) and 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (PE-rhodamine) were 
purchased from Avanti Polar Lipids Inc. Liposomes containing phospholipids, mannosylated 
cholesterol and cholesterol were formed by dehydration-rehydration.  Briefly, the liposome 
components were dissolved in a minimal volume of Folch (Chloroform: Methanol; 2:1 (v/v)) and mixed 
in a round bottomed flask at the molar ratios described in Table 1.  PE-Rhodamine (0.1% of mole 
ratio) was added to fluorescently label liposomes.  Solvents were evaporated using a rotary 
evaporator (Büchi Rotavapor R200) and the lipid film was rehydrated in pH 7.4 Phosphate Buffered 
Saline (PBS; GIBCO).  Size reduction of rehydrated lipids was achieved by extrusion using a LIPEX™ 
Thermobarrel Extruder or Avanti® Mini-Extruder 10 times through a polycarbonate membrane filter 
with 100, 200, 400 or 1000 nm pores (Whatman).    
 
Liposome Characterization 
Liposome concentration was determined using cholesterol and phospholipid assays (WAKO).  Size 
and zeta potential were determined using a zetasizer (nanoseries, Malvern).  For transmission 
electron microscopy (TEM) studies copper thin bar 200-mesh grids were coated with pioloform.  
Liposomes (2µl) were placed on the grid for 1 minute and blotted. The grid was negatively stained 
with a drop of (2% w/v) phosphotungstic acid (PTA) for 1 minute and again blotted followed by 
washing with deionized water. The grids were viewed the same day using a Hitachi H-7650 TEM.   
 
Cell Culture 
Human monocyte THP-1 cells were maintained in RPMI 1640 (BioSera) supplemented with 10% heat 
inactivated fetal bovine serum (FBS, BioSera) in a humidified atmosphere at 37°C and 5% CO2.  
THP1-XBlue™ cells are stably transfected THP-1 cells expressing secreted embryonic alkaline 
phosphatase (SEAP) gene which is induced by the transcription factors NF-κB and activator protein-1 
(AP-1).  THP1-XBlue™ cells were maintained in RPMI 1640 supplemented with 10% heat inactivated 
FBS and 200µg/ml of selection marker Zeocin™.  Cells were differentiated by the addition of 100nM 
phorbol myristate acetate (PMA) and incubated in a humidified incubator at 37°C and 5% CO2 for 72 
hours.  
 
Immunofluorescence Microscopy to Determine Mannose Receptor Expression  
THP-1 cells were seeded at 1x105 cells/ml in 96-well plates, differentiated and fixed with 4% 
paraformaldehyde (PFA) for 20 minutes.  Cells were blocked with 1% bovine serum albumin (BSA) 
and incubated with 0 or 1 μg/ml rabbit polyclonal mannose receptor antibody (Abcam) followed by 
goat anti-rabbit secondary antibody Alexa Fluor® 488 and counterstained with Hoechst 33342 and 
phalloidin-tetramethyl rhodamine isothiocyanate (TRITC).  Images were acquired using an INCELL 
1000 cell analyser and 10x objective. 
 
Liposome-Cell Interaction Study: High Content Cell Analysis 
A High Content Cell Analysis (HCA) method was developed for analysis of liposome-cell interaction to 
enable high throughput studies.  THP-1 cells were differentiated at a density of 1x105 cells/ml in 96-
well plates.  Rhodamine-labelled anionic, neutral and mannosylated liposomes were incubated with 
differentiated THP-1 cells in triplicate according to Table 2.  Cells were washed, fixed with 4% PFA 
and stained with phalloidin-fluorescein isothiocyanate (FITC) and Hoechst 33342.  HCA was carried 
out using INCELL 1000 analyser.  Images were acquired in three channels; excitation/emission 
wavelengths of 360/460nm (Hoechst 33342), 480/535nm (phalloidin-FITC) and 535/600nm 
(rhodamine tagged liposomes), 5 fields per well and analysed using INCELL1000 analyser software.  
Multi-target analysis module was used to segment nuclei, cells and liposomes (Figure 2) and count 
the number of liposomes associated with the identified cell regions.   
 
Liposome High Content Toxicity Screen 
Cellomics® Multiparameter Cytotoxicity 3 kit and an INCELL 1000 analyser were used to determine 
cytotoxicity following liposome treatment in differentiated THP-1 cells.  Cells were seeded in flat-
bottomed 96-well plates and were treated with rhodamine-labelled anionic, neutral and mannosylated 
liposomes at concentrations of 0, 100 or 300μM in triplicate and incubated at 37°C for 23.5 hours.  
Valinomycin (120μM) served as a positive toxic control.  Permeability and mitochondrial membrane 
potential (MMP) dyes were added to wells and incubated at 37°C for 30 minutes.  Cells were fixed 
with 4% PFA, permeablised and blocked.  Cytochrome c staining was carried out using a cytochrome 
c primary antibody and DyLight 649 secondary antibody.  Nuclei were stained using Hoechst.  Images 
were acquired by an INCELL 1000 analyser within 24 hours in 4 fields per well using 
excitation/emission wavelengths of 360/460nm (Hoechst 33342 dye), 480/535nm (Permeability dye), 
535/600nm (MMP dye) and 620/700nm (DyLight 649).  Cell loss, nuclear area, nuclear intensity, 
cytochrome c release, mitochondrial membrane potential and cell permeability were determined using 
INCELL analysis software using multi-parameter target analysis and the settings in Table 3.  Images 
were acquired at 10x objective magnification.   
 
Macrophage Activation Screen 
THP1-XBlue™ cells (NF-κB/AP-1 Reporter Monocytes) were differentiated for 72 hours at 1x106 
cells/ml in a 96 well plate.  PMA free media was replaced daily for a further 5 days to remove residual 
PMA.  Liposomes were added to cells in fresh media at 0, 100, 200 and 300μM final concentration in 
triplicate.  Cells were stimulated with 100ng/ml lipopolysaccharide (LPS) as a positive control.  After 
24 hours 20µl of media was removed and added to 180µl of QUANTI-Blue™.  After a 4 hour 
incubation absorbance was measured at 630nm using a multiplate reader to determine SEAP activity.  
 
THP-1 cells were differentiated in 24 well plates at 1x105 cells/ml.  Cells were incubated in fresh 
complete media (untreated); RPMI supplemented with 100ng/ml LPS or anionic, neutral, cationic or 
mannosylated liposomes at 100μM or 300μM for 24 hours.  Media was collected and stored at -80°C 
until assayed.  Production of a range of cytokines secreted following macrophage activation (IFNγ, IL-
1β, IL-2, IL-4, IL-5, IL-8, IL-10, IL-12p40, IL-13 and TNFα) were simultaneously determined using a 
MesoScale Discovery (MSD) multiplex assay.  MSD plates were analysed on a SECTOR Imager 
using the MSD DISCOVERY WORKBENCH® software. 
 
 
Statistics 
Results are expressed as means ± SD.  One way or two way ANOVA was used to test for differences 
between treatments with p-values < 0.05 considered significant, < 0.01 very significant and < 0.001 
highly significant. 
Results 
 
Liposome Characterization 
Particle size and zeta potential were determined for each batch of liposomes prepared.  Spherical 
liposomes (Figure 1) with representative average sizes for 3 batches following extrusion through 
200nm pore filters of cationic, anionic, neutral and mannosylated liposomes shown in Table 4 with 
polydispersity indices (PDI) of less than 0.227.  The zeta potential of liposomes composed of 50% 
cationic lipid DOTAP was 61.8 ± 6mV whilst anionic, neutral and mannosylated (MC6C) liposomes 
had mean surface charges of -68.3 ± 8mV, -4.4 ± 3mV and 45.2 ± 3mV. 
 
THP-1 cells as a Macrophage Cell Model: Mannose Receptor Expression 
THP-1 cells are a monocytic cell line that can be differentiated by phorbol esters into macrophage like 
cells (Tsuchiya et al., 1982, Daigneault et al., 2010, Lawlor et al., 2012, O'Sullivan et al., 2007) which 
express both SRs and MRs upon differentiation (Kohro et al., 2004, Liao et al., 1999). The visible 
presence of Alexa Fluor 488 (green fluorescence) in Figure 3B demonstrates MR expression in 
differentiated THP-1 cells, confirming this cell line as an appropriate in vitro model for mannosylated 
liposome targeting.  
 
High Content Cell Analysis (HCA) of Liposome Interaction with THP-1 cells 
A HCA protocol was established to count liposomes per cell.  Several conditions were screened 
including a range of liposome sizes (100nm to >1μm in diameter), concentrations (0 to 1mM), 
incubation times (0.5 to 24 hours) and temperatures (4 and 37°C).  Overall, HCA data (Figure 4) 
indicates that DOPS and mannosylated liposomes had significantly better cellular association 
compared to untargeted DOPC controls.   
 
Size can contribute significantly to cellular uptake efficiency of liposomes.  Cell association of anionic 
DOPS liposomes increased with increasing particle size (Figure 4G) while neutral DOPC and MC2C 
and MC4C mannosylated liposomes showed an increase up to 200nm however the cell association 
decreased with particles ≥ 400nm in diameter.  The most significant increases in liposome cell 
association when compared to unextruded counterparts were of MC4C 200 and 400nm (p < 0.001) 
and MC6C 200nm (p < 0.001) (Figure 4G).  DOPS and MC6C liposomes showed the greatest level of 
cell association with DOPS liposome association size dependent and MC6C liposome size 
independent in the 100 - 1000nm range.  In general, increasing liposome concentration lead to an 
increase in THP-1 cell association.  Significant increase in targeted liposome cell association 
particularly DOPS and MC6C liposomes was observed compared to concentration matching non-
target DOPC liposomes at all concentrations (Figure 4H).  Cells were treated with 200nm liposomes 
at 200µM and fixed after 0.5, 1, 2, 4 and 24 hours.  Cell association of DOPC, MC2C and MC4C 
liposomes did not significantly change over 24 hours. MC6C liposome cell association was 
significantly higher at all time points in comparison to neutral DOPC counterparts.  However, DOPS 
liposome cell association was significantly enhanced following 0.5 and 1 hour treatments but 
decreased after 24 hours.  Cell association of DOPS liposomes at 24 hours was almost 4-fold less 
than association of MC6C liposomes at the same time point.  Overall, optimal concentrations were 
above 100μM (Figure 4H) and incubation times greater than 2 hours (Figure 4I) for the leading DOPS 
and MC6C liposomes.   
 
Additionally liposome cell association at 4°C and 37°C was compared.  Cells were incubated either at 
4 or 37°C with 100μM of 200nm-sized rhodamine labelled anionic (DOPS), neutral non-mannosylated 
(DOPC) and mannosylated (MC2C, MC4C and MC6C) liposomes for 2 hours. THP-1 cell association 
of DOPS, MC4C and MC6C liposomes was highly significantly impeded at 4°C (p < 0.001) suggesting 
an active uptake process (Figure 5). 
 
Liposome Toxicity: Multiparameter Cytotoxicity Testing 
Differentiated THP-1 cells were used to assess the effects of liposome treatment on cell viability. 
Cationic (DOTAP), anionic (DOPS), neutral (DOPC) and mannosylated (MC2C, MC4C and MC6C) 
liposomes at 100μM and 300μM were incubated with differentiated THP-1 cells for 24 hours, fixed and 
stained. Negative controls were incubated under normal conditions and served as the healthy cell 
comparison for other treatments.  HCA was used to acquire and analyze images based on staining for 
nuclei, cell permeability, MMP and cytochrome c.   Chromatin condensation is associated with 
apoptosis which can be monitored by changes in nuclear size and intensity. The positive control 
valinomycin induced significant cell loss (p < 0.001) (Figures 6B&6I).  Significant cell loss was also 
found following 300μM treatments of mannosylated liposomes (Figure 6I).  Valinomycin treatment 
decreased the mean nuclear area (Figure 6J) and increased the total nuclear intensity albeit not 
significantly. Increased cell permeability occurs during necrosis, however, no significant elevation in 
permeability was determined following any liposome treatment (Figure 6L).  Valinomycin, and 300µM 
DOTAP, DOPS and MC2C liposome treatments induced a fall in MMP (Figure 6M), which is 
associated with apoptosis and cytochrome c release.  
 
Macrophage Activation: NFκB Activation and Cytokine Screen 
When dealing with targeting of any immune cell, including macrophages, it is of particular importance 
that the ability to activate the cells in question is compared for different carriers. In order to assess this 
response in our model system, NFκB activation and induction of a range of cytokines were 
determined, including cytokines associated with inflammation and a TH1 response such as TNFα, IL-
1β, IL-2, IL-12p70, IFNγ and IL-8 and a TH2 response such as IL-2, IL-4, IL-5, IL-10 and IL-13 (Table 
5).  NFκB can induce transcription of many pro-inflammatory genes such as TNFα, IL-1β, IL-6 and IL-
8 (Tak and Firestein, 2001). Here activation was assessed using a NFκB reporter cell line, THP1-
XBlue™ cells, following incubation with liposomes.  LPS stimulation of differentiated THP1-XBlue™ 
cells was used as a positive control and to validate the macrophage activation screen. A significant 
increase in NFκB activation compared to untreated cells was found following 24 hour treatment with 
the positive control LPS (p < 0.001) (Figure 7).  As expected, TNFα was significantly induced by LPS 
(p < 0.05) whilst elevations in mean concentrations of IL-1β, IFNγ and IL-8 compared to untreated 
cells were also observed, further validating this screening assay.  THP1-XBlue™ cell cytotoxic and 
immune reactivity to cationic, neutral, anionic and mannosylated liposomes are discussed in detail 
below. 
 
 
Cationic DOTAP Liposomes Induce High Levels of Toxicity and a Proinflammatory Response 
from Differentiated THP-1 cells 
DOTAP liposomes induced significant cell loss while increasing cell permeability, decreasing MMP 
and promoting cytochrome c release at 100 and 300μM indicative of both apoptosis and necrosis.  
Cytochrome c intensity was significantly reduced (p < 0.05) compared to healthy control cells 
following 300μM DOTAP liposome treatment suggestive of cytochrome c release (Figure 6).  DOTAP 
liposomes also induced a proinflammatory response in the macrophage-like cells with increases in IL-
1β and IFN-γ and decreases in IL-4 being observed, although these were not statistically significant 
(Table 5). 
 
 
Neutral DOPC Liposomes Induce Minimal Toxicity and Inflammatory Cytokine Production in 
Differentiated THP1 cells 
Cell loss resulted only from 300μM treatments with DOPC liposomes in THP-1 cells however, other 
signs of apoptosis or necrosis were not observed (Figure 6).  NFκB was significantly activated (p < 
0.05) following 24 hour DOPC liposome treatment at 100μM (Figure 7) and IL-12p70 was (non-
significantly) induced by a 300μM dose of DOPC liposomes (Table 5).  In general however, DOPC 
liposome treatment in THP-1 cells resulted in reduction of immune mediators compared to untreated 
control cells. 
 
Anionic DOPS Liposomes at High Concentrations Induce Toxicity and Immune Reactivity in 
Differentiated THP1 cells 
Anionic liposomes were composed of DOPS which targets macrophage scavenger receptors by 
mimicking apoptotic cells.  At the higher concentration of 300μM DOPS, liposomes were found to 
reduce cell number and MMP, a sign of induced apoptosis (Figure 6).  Furthermore, NFκB activity was 
significantly induced (p < 0.001) at 300μM and was concentration dependent (Figure 7).  IL-8 is an 
important chemokine for neutrophil recruitment and therefore is upregulated during inflammation.  
Significant induction of IL-8 (p < 0.05) was observed after 24 hour treatment (6615.5±1400.6pg/ml) 
with 300μM DOPS liposomes (Table 5).  DOPS liposomes were the most potent inducer of cytokines 
and chemokines in differentiated THP-1 cells with all measured immune mediators induced except IL-
12p70.   
 
 
 
Mannosylated Liposomes show Immunosuppressive Effects but at High Concentrations 
Induce Toxicity in Differentiated THP1 cells 
Significant cell loss was found following cell treatment of cells with mannosylated liposomes at 300μM 
(Figure 6I), of which MC2C liposomes caused significant (p < 0.01) increase in nuclear intensity 
(Figure 6K). Of the targeted liposomes, MC2C liposomes at 300μM caused the most significant effect, 
leading to apoptosis in THP-1 cells after 24 hours with a highly significant cell loss (p < 0.001), a 
significant increase in nuclear intensity (p < 0.01) and a decrease in MMP.  MC6C liposomes 
composed of mannosylated cholesterols with longer linker length at 300μM induced significant cell 
loss but all other measures of cell health were comparable with untreated control cells.  However, 
mannosylated liposome treatment showed no significant difference in NFκB activation compared to 
untreated cells but in comparison to non-mannosylated DOPC liposome treatment at equal 
concentrations, NFκB activation was significantly lower following 200μM MC4C (p < 0.01), 300μM 
MC4C (p < 0.05), 200μM MC6C (p < 0.05) and 300μM MC6C (p < 0.05) liposome treatment (Figure 
7).  However, although MC2C liposomes did not significantly alter NFκB activation, they induced 
increased synthesis of IL-12p70 (to a lesser extent than DOPC liposomes), IFNγ (at 100μM, similar to 
MC4C), IL-13, IL-5 and IL-10, indicating that they elicited a cytokine response.   MC6C liposomes also 
led to IFNγ and IL-8 suppression compared to untreated control levels.  Previously, TNFα, IL-1β and 
cytokine-induced neutrophil chemoattractant-1 (CINC-1) levels have been monitored in vitro in 
alveolar macrophages and in vivo in rat lungs following mannosylated liposome delivery of 
dexamethasone (Wijagkanalan et al., 2008a).  However, the ability of mannosylated liposomes to 
induce immune reactivity alone has not been investigated.   
 
Discussion 
An essential step in targeted cellular delivery is internalization of the carrier system by the target cells.  
Cell interaction of liposomes has been studied using a range of techniques such as flow cytometry, 
confocal microscopy and spectrofluorimetry (Cryan et al., 2006, Wijagkanalan et al., 2008b, Lawlor et 
al. 2011, Gilleron et al., 2013).  We have developed a more powerful method for studying particle-cell 
interaction using High Content Analysis (HCA) that combines imaging and drug/carrier quantification, 
from single cells to cell populations, in a high throughput format (Hibbitts et al., 2011, Lawlor et al., 
2011).  HCA also enables multiple, parallel experiments to be carried out to optimize the liposome 
formulation for macrophage targeting.   
 
HCA assessment of liposome association with differentiated THP-1 cells showed overwhelming 
confirmation of DOPS and MC6C liposomes as lead delivery platforms (Figure 4).  Moreover, the level 
of cell interaction of mannosylated liposomes also appeared to be linker dependent with levels for 
liposomes composed of MC6C greater than those composed with MC4C which both facilitated higher 
uptake than MC2C liposomes.  Engel et al. investigated the influence of spacer length between alkyl 
mannosides and liposome surface, on liposome interaction with phagocytic cells (Engel et al., 2003).  
Spacers were 0 to 8 ethyleneoxy units long (Man0 - Man8) with longer spacers mannosylated 
liposome uptake by mannose receptor expressing cells was more enhanced.  Furthermore, Gal-C6-
Chol composed liposomes were previously shown to mediate a higher DNA transfection efficiency 
than Gal-2-Chol and Gal-C4-Chol liposomes (Kawakami et al., 1998). 
 
In general, nanoparticle-induced toxicity is connected to particle size and surface chemistry (Ai et al., 
2011).  Smaller liposomes can be more toxic than larger liposomes (Mayhew et al., 1987).  
Additionally a study previously compared the toxicity of liposomes composed of cationic (SA and 
cardiolipin), anionic (phosphatidylglycerol and phosphatidylserine) or neutral (phosphatidylcholine or 
dipalmitoylphosphatidylcholine) lipids (Mayhew et al., 1987).  Toxicity was established as inhibition of 
cell growth and determined following exposure to 200μM, 130-3000μM and 3000-4000μM cationic, 
anionic and neutral liposome formulations in a range of human cell lines (Mayhew et al., 1987).  It was 
observed that SA containing liposomes were toxic to cells and negatively charged liposomes had 
higher toxic effects on cells than similar uncharged formulations. However, inhibition of cell growth 
alone was used as a marker of toxicity. Here, HCA allowed the screening of multiple parameters 
including cell number to determine cell health in differentiated THP-1 cells following liposome 
treatment for 24 hours.  For these assays the ionophor valinomycin served as a positive control and 
validated the assay in terms of detection of changes in cell number, nuclear morphology, cell 
permeability, mitochondrial membrane potential (MMP) and cytochrome c release.  Typically, assays 
such as MTT are used to assess cell viability but this method enables more subtle changes in cell 
health to be detected with more detail.  Drugs and compounds affect cell health at various levels and 
cellular changes can vary depending on concentration and exposure time to these materials.  
Measuring a single parameter or end point may not provide the information necessary to determine 
an accurate cytotoxicity profile and under certain conditions may lead to false positive or false 
negative results (McKim Jr, 2010). 
 
Aside from toxicity, drug delivery systems can also induce immune responses, the extremes of which 
have been witnessed in clinical trials and in some cases have been fatal (Cotrim and Baum, 2008).  
To assess the effects of the liposome carriers on immune reactivity in differentiated THP-1 cells we 
looked at NFκB activation and at cytokine/chemokine induction following 24 hours treatment with LPS 
(positive control) and liposomes.  NFκB is a transcription factor that can be activated through various 
receptors including TLRs and TNF receptors and has a central role in inflammation (Tak and 
Firestein, 2001).   
 
DOTAP liposomes significantly reduced cell numbers at 100μM and 300μM (p < 0.05), increased cell 
permeability, reduced MMP and lead to significant cytochrome c release indicating the induction of 
both necrosis and apoptosis in these cells.  DOTAP is a cationic lipid that has been shown to cause 
toxicity in macrophages (Filion and Phillips, 1997, Filion and Phillips, 1998).  DOTAP liposomes also 
induced an inflammatory response in the macrophage-like cells with increases in IL-1β and IFN-γ and 
decreases in IL-4 (Table 5).  DOTAP containing liposomes at 100µM have been shown to down-
regulate TNFα synthesis in activated macrophages harvested from mice (Filion and Phillips, 1998) 
and therefore the lack of TNFα induction following DOTAP liposome treatment was expected. 
 
Activation of the mannose receptor has previously been shown to have an anti-inflammatory effect 
with impaired NFκB activation (Chieppa et al., 2003, Xu et al., 2010).  In this study, mannosylated 
liposomes reduced NFκB activation in differentiated THP-1 cells compared to non-mannosylated 
DOPC liposomes in a concentration- and mannosylated cholesterol linker length-dependent manner.  
In general this lack of immune reactivity of mannosylated liposomes was corroborated in cytokine 
screens.  
 
Conclusions 
Overall, a range of liposomes were screened for their targeting ability and biocompatibility with 
macrophage cells. HCA was applied to study the interaction of liposomes with macrophage cells, 
including representative formulations of neutral, charged and targeted liposomes. Anionic and 
mannose (MC6C) coated liposomes showed the most significant cellular interaction, specifically 
DOPS and mannosylated MC6C liposomes emerged as the leading formulations for intracellular 
delivery.  At the lower concentration range tested liposomes were non-toxic, however, DOPS 
liposomes caused an inflammatory response in differentiated THP-1 cells.  MC6C liposomes showed 
immunosuppressive characteristics such as a hampering of NFκB activation and reduced IL-8 and 
IFNγ production.  HCA allowed liposome formulation interaction with macrophages to be assessed in 
a high throughput format for the first time.  
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Tables: 
 
Table 1: Prepared liposome compositions: DOTAP (liposome positive control), DOPS (anionic), 
DOPC (neutral), mannosylated (MC2C, MC4C, MC6C) liposomes. 
 
Liposome 
Nomenclature 
Molar Ratios of Constituent Lipids 
DOTAP DOPS DOPC Cholesterol Mann-C2-Chol Mann-C4-Chol Mann-C6-Chol 
DOTAP 50   30 20       
DOPS   70   30       
DOPC     70 30       
MC2C     70 22.5 7.5     
MC4C     70 22.5   7.5   
MC6C     70 22.5     7.5 
 
 
Table 2: Liposome treatments for differentiated THP-1 cell –interaction assessment by high content 
screening 
 
HCA Assay Variable Size (nm) Concentration (μM) Time (hours) 
Liposome Size Unextruded, 100, 200, 
400, 1000 
200 2 
Liposome 
Concentration  
200 0, 50, 100, 200, 300, 
1000 
2 
Liposome Incubation 
Time 
200 200 0.5, 1, 2, 4, 24 
 
 
Table 3: Representative parameters for high content screening of liposome toxicity in THP-1 cells 
 
Parameters Wavelength (Ex/Em, nm) Analysis Settings 
Nucleus 360/460 Region growing; min. area 33.2μm2 
Cell - Collar; 11μm 
Permeability 480/535 Reference; In Cell 
Mitochondrial Membrane Potential 535/600 Reference; In Cell 
Cytochrome c 620/700 Reference; In Cell 
 
Table 4: Sizing and zeta potentials of liposomes extruded to 200nm (n = 3) 
 
Liposome Average Size (d50 nm) Polydispersity Index 
(PDI) 
Zeta Potential 
(mV) 
DOTAP 198.9 ± 39 0.214 61.8 ± 6 
DOPS 168.6 ± 28  0.227 -68.3 ± 8 
DOPC 190.3 ± 22 0.164 -4.4 ± 3 
MC2C 206.9 ± 35  0.145 36.9 ± 14 
MC4C 204.7 ± 15 0.207 44.9 ± 5 
MC6C 178.2 ± 11 0.108 45.2 ± 3 
Table 5 Cytokine production in differentiated THP-1 cells following 24 hour liposome treatment.   
Differentiated THP-1 cells were incubated for 24 hours with complete media (negative control), 100ng/ml LPS (positive control) or DOTAP (liposome positive 
control), DOPS (anionic), DOPC (neutral), mannosylated (MC2C, MC4C, MC6C) liposomes at 100μM or 300μM.  Supernatants were analyzed using a MSD 
10-plex cytokine assay. 
Data represented as means ± SD. (n = 3) Statistical significance was determined by two-way ANOVA with Bonferroni’s Post-hoc test (* p < 0.05, ** p < 0.01, 
*** p < 0.001) 
 
Treatment Concentr
ation 
TH1 TH2 
TNFα IL-1β IL-2 IL-8 IL-12p70 IFNγ IL-4 IL-5 IL-10 IL-13 
Untreated - 272.5 ± 104.9 4.6 ± 2.2 5.4 ± 3.3 2415 ± 1620.1 4.1 ± 5.4 17.2 ± 11.9 5.3 ± 4.0 3.9 ± 3.5 41.9 ± 17.9 37.7 ± 7.1 
LPS 100ng/ml 2316.4 ± 2860.4 * 85.3 ± 114.2 7.6 ± 4.9 5867.4 ± 4638 11.3 ± 7.6 37.8 ± 25.6 9.0 ± 5.5 7.5 ± 6.3 68.3 ± 53.4 52.0 ± 17.8 
DOTAP 100μM 290.3 ± 88.1 69.9 ± 87.5 6.1 ± 2.9 2768.8 ± 1843.4 4.0 ± 5.7 21.6 ± 12.4 4.8 ± 2.5 4.5 ± 3.7 39.3 ± 8.5 50.5 ± 0.8 
300μM 380.3 ± 63 43.1 ± 24.5 4.9 ± 1.5 2205.2 ± 1576.6 0.5 ± 0.8 13.7 ± 3.5 4.2 ± 1.6 3.1 ± 1.0 37.4 ± 7.9 48.7 ± 18.4 
DOPS 100μM 379 ± 60.6 6.9 ± 3.7 6.2 ± 1.5 1243.7 ± 458.1 3.6 ± 6.3 14.2 ± 7.1 4.5 ± 2.7 3.5 ± 2.2 34.3 ± 7.2 53.4 ± 7.9 
300μM 631.9 ± 238.3 36.6 ± 16.3 7.6 ± 0.9 6615.5 ± 1400.6 * 6.7 ± 2.1 22.7 ± 2.1 8.1 ± 3.3 8.0 ± 1.2 52.9 ± 7.7 57.3 ± 10.0 
DOPC 100μM 286.7 ± 33.9 6.3 ± 4.0 3.6 ± 2.5 1892.6 ± 1191.2 2.9 ± 5.1 11.1 ± 12.3 3.7 ± 4.6 3.1 ± 2.5 30.1 ± 13.6 47.4 ± 8.0 
300μM 418 ± 116.8 11.0 ± 8.6 4.9 ± 2.6 2283.1 ± 1644.2 34.6 ± 59.9 11.9 ± 6.1 2.6 ± 1.2 3.5 ± 1.9 37.1 ± 13.9 50.5 ± 9.4 
MC2C 100μM 294.9 ± 45.4 6.3 ± 4.3 7.4 ± 3.7 1426.9 ± 864.4 22.7 ± 20.1 25.4 ± 37.9 5.3 ± 6.8 6.4 ± 4.2 59.2 ± 29.8 56.5 ± 9.1 
300μM 325.8 ± 26.7 9.2 ± 8.0 11.1 ± 6.1 2072.5 ± 2043.2 3.2 ± 2.3 15.2 ± 6.0 3.4 ± 2.0 3.1 ± 2.7  39.9 ± 11.6 49.5 ± 5.7 
MC4C 100μM 215.8 ± 93.9 4.0 ± 2.1 4.9 ± 2.8 1031.7 ± 680.6 2.0 ± 3.4 26.1 ± 35.9 3.0 ± 3.2 2.6 ± 2.3 31.2 ± 9.8 35.0 ± 11.5 
300μM 305 ± 89.5 10.9 ± 7.3 3.2 ± 1.8 1769.5 ± 1485.4 1.3 ± 2.3 10.8 ± 1.7 3.5 ± 3.2 2.0 ± 1.6 23.4 ± 6.8 48.6 ± 9.6 
MC6C 100μM 259.5 ± 51.4 4.7 ± 2.0 7.0 ± 4.5 1562.9 ± 972 5.9 ± 7.1 13.2 ± 13.2 4.4 ± 4.5 3.9 ± 5.5 62.9 ± 43.4 56.7 ± 18.1 
300μM 320.3 ± 32.6 15.3 ± 12.5 4.2 ± 2.3 1944.1 ± 1688.1 8.1 ± 7.1 10.5 ± 7.9 3.5 ± 1.4 6.9 ± 2.8 51.6 ± 5.1 64.8 ± 8.1 * 
Figure 1: Transmission electron microscopy images of DOPS:Chol (7:3) liposomes at 100 kV 
high voltage and 50,000x magnification negatively stained with 2% phosphotunstic acid. 
 
Figure 2: INCELL cell analysis.  Images acquired at 3 excitation/emission wavelengths 
360/480 blue (nuclei; Hoechst 33342), 480/535 green (cells; phalloidin-FITC) and 535/620 
(red; liposomes).  Nuclei, cells and liposomes were segmented.  Fused images show overlays 
of the segmentation.  The number of liposomes in each cell was counted. 
 
Figure 3: Immunofluorescence to determine the expression of mannose receptor by 
differentiated THP-1 cells.  Fixed cells were blocked with 1% BSA followed by incubation with 
(A) 1% BSA or (B) polyclonal mannose receptor antibody (1μg/ml).  Cells were then incubated 
with secondary Alexa Fluor 488 antibody (green) and stained with Hoechst 33342 (nuclei; 
blue) and phalloidin-TRITC (F-Actin; Red).  Images were acquired using an INCELL 1000 
analyser with a 10x objective. 
 
Figure 4:  Cell association analysis by INCELL HCA of rhodamine labelled liposomes with 
differentiated THP-1 cells.  Cells were incubated without liposomes (untreated) or with 
fluorescently tagged (rhodamine; red) anionic (DOPS), non-mannosylated neutral (DOPC) 
and mannosylated liposomes (7.5% MC2C, MC4C and MC6C), fixed and stained for nuclei 
(Hoechst; blue) and F-Actin (phalloidin-FITC; green). Images were acquired by an INCELL 
1000 cell analyser with a 20x objective.  Representative images show (A) untreated cells and 
cells treated with 200nm DOPS liposomes at concentrations of (B) 50, (C) 100, (D) 200, (E) 
300 and (F) 1000μM for 2 hours. Liposomes were counted per cell using INCELL 1000 
analysis software following treatment with liposomes ranging (G) in size at 200µM for 2hrs, 
(H) in concentration at 200nm for 2hrs and (I) in incubation time at 200nm and 200µM.  
Data represented as means ± SD (n = 6)  
Statistical differences were determined by two-way ANOVA with Bonferroni’s post-hoc test (* 
p < 0.05, ** p < 0.01) vs. unextruded liposome or DOPC-treated counterparts 
 
Figure 5: Cell association analysis by INCELL HCA of rhodamine labelled liposomes by 
differentiated THP-1 cells at 4°C and 37°C.  Cells were incubated without liposomes 
(untreated) or with 100μM 200nm fluorescently tagged (rhodamine; red) anionic (DOPS), 
neutral non-mannosylated (DOPC) and mannosylated (7.5% MC2C, MC4C and MC6C) 
liposomes at 4 and 37°C for 2 hours. THP-1 cells were fixed and stained for nuclei (Hoechst; 
blue) and F-actin (phalloidin-FITC; green) and images were acquired using an INCELL 1000 
cell analyser.  Representative images show (A) untreated cells and cells treated with 100μM 
of 200nm MC6C liposomes at (B) 4°C and (C) 37°C for 2 hours.  Images were analysed and 
liposomes counted per cell (G).  Data represented as means ± SD (n = 6)  
Statistical differences were determined by two-way ANOVA with Bonferroni’s post-hoc test (* 
p < 0.05, ** p < 0.01, *** p < 0.001) 
Figure 6:  High content cell assessment of liposome associated cytotoxicity in differentiated 
THP-1 cells.  Representative images show control treatments with cells treated with (A) 
complete media as a negative control, (B) 120μM valinomycin as a positive control and cells 
treated with 100µM (C) DOTAP, (D) DOPS, (E) DOPC, (F) MC2C, (G) MC4C and (H) MC6C 
liposomes.  Images were acquired by an INCELL 1000 analyser in 4 channels and (A-H) 
show nuclei (Hoechst; blue), cell permeability (green) and mitochondrial membrane potential 
(MMP; red).  Differentiated THP-1 cells were treated with 100μM
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 anionic 
(DOPS), neutral (DOPC) or mannosylated liposomes. Positive controls were treated with 
120μM valinomycin or 100 or 300μM cationic (DOTAP) liposomes.  Cells were treated for 24 
hours, fixed and stained.  
 
Figure 7: Liposome induced NFκB Activation in THP1-XBlue™ Cells.  Differentiated THP1-
XBlue™ reporter cells were incubated with anionic (DOPS), neutral (DOPC) and 
mannosylated (MC2C, MC4C and MC6C) liposom s at 100µM and 300µM for 24 hours.  
Positive controls were treated with 100ng/ml LPS.  Mean absorbance determined following 
treatment with 100µM DOPC is shown by the dashed line.  SEAP activity was determined by 
absorbance at 630nm. 
Data represented as means ± SD (n = 3) 
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